Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: The experience of the European institute of oncology on 854 patients in 10 years

Annals of Surgery

Volumn 247, Issue 2, 2008, Pages 315-319

  Intra, Mattia ^a,c   Rotmensz, Nicole ^a   Veronesi, Paolo ^a,b   Colleoni, Marco ^a   Iodice, Simona ^a   Paganelli, Giovanni ^a   Viale, Giuseppe ^a,b   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CARCINOMA IN SITU; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MICROMETASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; STEREOTACTIC BIOPSY; TISSUE SECTION;

ACADEMIES AND INSTITUTES; ADULT; AGED; AXILLA; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TIME FACTORS;

EID: 38549137769     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31815b446b     Document Type: Article

References (27)

1. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430-1441.
2. Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol. 2001;8:275-277.
3. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-7720.
4. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. 4 Arch Surg. 2003;138:309-313.
5. Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast. 2005;14:520-522.
6. Rosen PP, Oberman H. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology; 1993.
7. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11:167.
8. Page D, Anderson T. Metastasis of breast cancer. In: Page D, Anderson T, eds. Diagnostic Histopathology of the Breast. Edinburg, Scotland: Churchill Livingstone; 1988:321-322.
9. Veronesi U, Zurrida S, Mazzarol G, Viale G. Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. World J Surg. 2001;25:806-808.
10. Sobin LH, Wittekind C. TNM Classification of Malignant tumours, UICC. New York: Wiley-Liss; 2002.
11. Tavassoli FA. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol. 1998;11:140-144.
12. Pendas S, Dauway E, Giuliano R, Ku NN, Cox CE, Reintgen DS. Sentinel node biopsy in DCIS patients. Ann Surg Oncol. 2000;7:15-20.
13. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol. 2000;7:636-642.
14. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67:513-519.
15. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516-526.
16. Wilkie C, White L, Dupont E, et al. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190:563-566.
17. Mabry H, Giuliano A, Silverstain M. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg. 2006;192:455-457.
18. Kelly TA, Kim JA, Patrick R. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg. 2003;186:368-370.
19. Fraile M, Gubern JM, Rull M, et al. Is it possible to refine the indication for sentinel node biopsy in high-risk ductal carcinoma in situ? Nucl Med Commun. 2006;27:785-789.
20. Youngson BJ, Liberman L, Rosen PP. Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy. 4 Am J Clin Pathol. 1995;103:598-602.
21. Diaz LK, Wiley EL, Venta LA. Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR Am J Roentgenol. 1999;173:1303-1313.
22. Leidenius M, Salmenkivi K, von Smitten K, Heikkila P. Tumourpositive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol. 2006;94:380 -384.
23. Carter BA, Jensen RA, Simpson JF, Page DL. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Pathol. 2000;113:259-265.
24. Diaz NM, Vrcel V, Centeno BA, Muro-Cacho C. Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes. Adv Anat Pathol. 2005;12:7-9.
25. Cody HS III. Sentinel lymph node biopsy for DCIS: are we approaching consensus? Ann Surg Oncol. 2007;14:2179-2181.
26. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497-502.
27. Intra M, Veronesi P, Gentilini OD, et al. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007;95:175-189.